

INDUSTRY SUPPORTED SESSIONS PROGRAMS

INDUSTRY SUPPORTED SESSION BY CHUGAI

Current and Future Perspective of Interleukin-6 Blocking Therapy on Autoimmune Diseases

Wednesday, 16 May 15:30-17:30

Auditorium II

10 years' history since approval of tocilizumab on rheumatoid arthritis in Japan

Speaker: Takao Koike, Professor Emeritus, Hokkaido University, Japan

New safety information of tocilizumab on rheumatoid arthritis

Speaker: Tatsuya Atsumi, Professor, Hokkaido University Graduate School of Medicine, Japan

Cumulative and updated evidence of IL-6 signaling inhibition on autoimmune diseases

Speaker: Tsutomu Takeuchi, Professor, Keio University School of Medicine, Japan

New era of large vessel vasculitis treatment

Speaker: Yoshiya Tanaka, Professor, Hospital of the University of Occupational and Environmental Health, Japan

Future perspective of tocilizumab

Speaker: Kazuhiko Yamamoto, Deputy Director, Center for Integrative Medical Sciences, and Team Leader, Laboratory for Autoimmune Diseases, RIKEN, Japan

INDUSTRY SUPPORTED SESSION BY INOVA

Friday, 18 May 12:30-14:00

Auditorium II

Changing the paradigm for Autoimmune testing using a novel particle-based multi-analyte test (PMAT) system

Introduction of a novel particle-based multi-analyte test (PMAT) system as an aid in the diagnosis of autoimmune diseases

Speaker: Michael Mahler

Detection of autoantibodies in the diagnosis of antiphospholipid syndrome (APS) assessed using the PMAT system

Speaker: Pier Luigi Meroni

Multi-analyte detection of autoantibodies in the diagnosis of autoimmune liver diseases

Speaker: Nicola Bizzaro

The novel PMAT system shows excellent performance characteristics for the diagnosis of Celiac disease

Speaker: Peter Martis

Multi-analyte detection of autoantibodies in ANA associated rheumatic disease (AARD) improves the clinical assessment

Speaker: Carlos von Muehlen

Changing the paradigm in autoimmune myositis testing and impact on autoimmune laboratory

Speaker: Marvin Fritzler